Andrew D.J. Pearson

机构：LifeArc, Pearson (United Kingdom) · ORCID：0000-0002-8738-5913

发表论文 355 篇 · 总被引 19152 次 · h-index 70

代表论文

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial (2024 · Journal of Clinical Oncology · 被引 27)
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed (2023 · Journal of Clinical Oncology · 被引 22)
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration (2023 · European Journal of Cancer · 被引 17)
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents (2023 · Journal of Clinical Oncology · 被引 15)
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum (2025 · Pediatric Blood & Cancer · 被引 13)
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial (2025 · Journal of Clinical Oncology · 被引 11)